1. Introduction {#sec1}
===============

There is considerable evidence from epidemiological research, meta-analysis \[[@B1], [@B2]\], and prospective clinical trials \[[@B3], [@B4]\] to support an independent role for fasting and postprandial plasma triglycerides (TG) as a risk factor for cardiovascular disease (CVD). Increased plasma remnants of triglyceride-rich lipoproteins (TRLs), caused by delayed elimination of the same, has been shown to be prospectively associated with angiographic evidence of atherosclerosis and cardiac events \[[@B5]\]. Postprandial hypertriglyceridaemia is associated with two other well established cardiovascular risks---IR and obesity---both of which are prevalent in PCOS. An increase in postprandial lipoproteins is often found in IR states \[[@B6]\] and hyperinsulinaemia itself appears to delay and exacerbate postprandial accumulation of intestinally derived chylomicrons \[[@B7]\]. Obesity, especially visceral adiposity, also contributes to a magnified postprandial TG response \[[@B8], [@B9]\].

Postprandial hypertriglyceridaemia may be a plausible mechanism by which PCOS increases cardiovascular risk. Whilst numerous studies have investigated plasma lipid profile under fasting conditions in women with PCOS, few have investigated changes in the postprandial setting. In a previous study by Velázquez M et al. a strong positive correlation between postprandial TG and increasing waist-to-hip ratio (WHR) was demonstrated \[[@B10]\]. That study evaluated overweight (BMI 27.41 ± 0.50 kg/m^2^) PCOS women and compared them to lean PCOS women and lean control subjects. There were no obese controls and there was no analysis of the influence of androgens on postprandial hypertriglyceridaemia \[[@B10]\]. A separate study by Bahceci et al. evaluated postprandial responses to an oral fat tolerance test, comparing lean PCOS women with lean controls (BMI 23.5 ± 2.6 kg/m^2^ versus 23.1 ± 4.0 kg/m^2^; *p* \> 0.05) \[[@B11]\]. There were no obese or overweight controls in this study. They showed that PCOS women had higher baseline insulin levels, IR as assessed by homeostatic model assessment-IR (HOMA~IR~), AUC-TG, AUC-total-cholesterol, AUC-very-low-density lipoprotein cholesterol (AUC-VLDL-chol), and AUC-apoB. Surprisingly, though, AUC-insulin did not differ between the two groups. As with the study by Velázquez M et al., no analyses were reported between androgens and postprandial lipids \[[@B11]\].

It is also unclear whether postprandial hypertriglyceridaemia is mainly due to the contribution of intestinally derived apoB-48 containing chylomicrons or hepatically derived apoB-100 containing VLDL particles. Both VLDL and chylomicrons share a common lipolytic pathway and are hydrolysed by lipoprotein lipase (LPL), an enzyme predominantly found on the endothelial surfaces of the capillaries of adipose tissue, heart, and skeletal muscle. Hydrolysis results in the formation of a spectrum of smaller, denser particles. There are a number of described receptor mediated pathways through which these particles may eventually be cleared from the circulation \[[@B12]\]. Traditionally it has been difficult to assess what proportions of TRLs are chylomicrons and VLDL. However, using ELISA, it is now possible to directly measure the quantity of apoB-48 and hence chylomicron particles, in whole plasma \[[@B13], [@B14]\].

We sought to investigate whether the postprandial glucose and insulin and lipid and lipoprotein responses, including that of apolipoprotein B-48 (apoB-48) containing chylomicrons, to a mixed meal are different in obese PCOS women when compared to obese control subjects and whether differences, if any, are related to obesity, insulin resistance (IR), hyperandrogenaemia, or PCOS status.

2. Methods {#sec2}
==========

2.1. Subjects {#sec2.1}
-------------

Fifty-two obese premenopausal women with (*n* = 26) and without (*n* = 26) PCOS were recruited. Women with PCOS were recruited from the endocrinology outpatient clinics (Tallaght Hospital, Dublin, Ireland). Normal women were recruited by local advertisement. PCOS was defined according to the National Institute of Health (NIH) criteria as chronic oligomenorrhea (fewer than nine menstrual cycles per year) and clinical and/or biochemical evidence of hyperandrogenism, in the absence of other disorders causing the same phenotype \[[@B15]\]. Clinical criteria included hirsutism with a Ferriman-Gallwey score greater than 9, acne, or male pattern alopecia; biochemical criteria included total testosterone, androstenedione, or dehydroepiandrosterone sulphate (DHEAS) greater than the laboratory reference range. All normal subjects were eumenorrheic with testosterone levels within the normal range and were studied in the follicular phase of the menstrual cycle. Subjects were excluded if they were younger than 18 years old or older than 45 years old; were non-Caucasian, pregnant, or lactating; had a recent or chronic illness or medication likely to influence results; or were taking any medications likely to influence the results including hormonal contraception, antihypertensives, lipid-lowering medications, and antiplatelet or anti-inflammatory agents. Fourteen women in the PCOS group and 3 women without PCOS had a first-degree relative with type 2 diabetes mellitus. All study subjects gave their written signed consent to the study, which was approved by the Research Ethics Committee of Tallaght Hospital and St. James\'s Hospital (Dublin, Ireland).

2.2. Clinical Protocol {#sec2.2}
----------------------

This was a cross-sectional study. All subjects had their height measured with a Harpenden stadiometer and weight measured in light clothing. BMI was calculated as weight (kg)/height squared (m^2^). Waist circumference (WC) and hip circumference (HC) were measured with a nondistensible flexible tape, and WHR was calculated accordingly. All subjects also underwent estimation of body composition including percentage body fat (%BF) and percentage lean mass (%LM) using bioimpedance analysis using the Bodystat 1500 system (Bodystat Ltd., UK).

2.3. Frequently Sampled Intravenous Glucose Tolerance Test (fsIVGTT) {#sec2.3}
--------------------------------------------------------------------

Subjects attended the Clinical Investigation Unit after a 12-hour overnight fast and were requested to refrain from vigorous exercise and alcohol on the day prior to their fsIVGTT. On the morning of the fsIVGTT, two cannulae were inserted into the antecubital veins of both forearms. A fasting blood sample was taken from cannula 1. Then a bolus of 50% glucose solution (0.3 g/kg body weight (BW)) was infused into cannula 2 over a 1-minute period followed by 20 mL of 0.9% saline. Twenty minutes later, a dose of insulin (0.03 U/kg BW) was infused into the same cannula (cannula 2), which was then removed at 30 min after initiation of glucose administration. Meanwhile, blood was sampled through cannula 1 at frequent intervals over a 3-hour period (−5, 0, 2, 4, 8, 19, 22, 30, 40, 50, 70, 90, and 180 min after the start of the glucose injection) for determination of glucose and insulin at each time point. Blood samples were spun at 3000 rpm for 10 min after which the plasma was aliquoted and stored at −80°C until required for future analysis. Insulin sensitivity (*S* ~I~), glucose effectiveness (*S* ~G~), acute insulin response (AIR~G~), and disposition index (DI) were estimated using the MINMOD computer program (version 3.0, copyright R. N. Bergman).

2.4. Mixed Meal and Sampling {#sec2.4}
----------------------------

Following a 12-hour overnight fast, subjects came to the Clinical Investigation Unit in Tallaght Hospital for blood sampling and a high calorific meal. The mixed meal was designed and analyzed by a qualified dietician. It consisted of 948 kcal. 48% of the total calories were derived from fat (20% saturated, 16% monounsaturated, and 8% polyunsaturated). 36%  and  15% of the calories were derived from carbohydrate and protein, respectively. The meal was ingested within 20 minutes after baseline bloods. Bloods were taken at 2, 4, 6, and 8 hours after ingestion of the meal. Subjects were advised to restrict their physical activity to the minimum until the end of the sampling period.

2.5. Laboratory Methods {#sec2.5}
-----------------------

### 2.5.1. Hormones, Glucose, HbA1c, Lipids, and Apolipoproteins A-I, A-II, and B {#sec2.5.1}

Glucose was measured by an enzymatic (hexokinase) method on the Roche P Module (Roche, Stockholm, Sweden) and insulin was measured by electrochemiluminescence immunoassay on the Roche E Module (coefficients of variation (CVs) \<5% for both). Glucose and insulin levels were used to calculate HOMA~IR~. Nonesterified fatty acids (NEFA) were measured by a kit using the Randox Colorimetric Method (Randox, Antrim, UK) and analyzed on a Hitachi modular analyzer (Tokyo, Japan) (CV \< 5%). Luteinising hormone (LH), follicle stimulating hormone (FSH), sex hormone binding globulin (SHBG), DHEAS, oestradiol, thyroid stimulating hormone (TSH), free thyroxine (fT4), prolactin, and cortisol were measured by standard chemiluminescence immunoassays (CVs \< 5% for all). Total testosterone was measured by electrochemiluminescence immunoassay on the Roche E Module. Free androgen index (FAI) was calculated by the following formula: FAI = 100 × total testosterone/SHBG. Androstenedione was measured by radioimmunoassay (CV \< 5%). Total-cholesterol, TG, and HDL-C were measured using standard laboratory techniques (CV \< 5%). LDL-C was calculated using the Friedewald equation. Apolipoproteins A-I (apoA-I), A-II (apoA-II), and B (apoB) were measured by standard nephelometry on a BNII nephelometer (Dade Behring, Deerfield, IL) (CV \< 5%).

### 2.5.2. ApoB-48 ELISA {#sec2.5.2}

ApoB-48 was measured using a commercially available ELISA kit (AKHB48, Gentaur BVBA corporation) and using a modified version of the method described by Lorec et al. \[[@B13]\]. The anti-apoB-48 coated plate is initially washed to remove buffer. The appropriately diluted samples are added to the plate and left to react for one hour. Samples were diluted 1 : 250 to ensure that the concentration was not above the assay range. The plate was subsequently washed 4 times, and biotin-conjugated anti-apoB-48 antibody is added. This binds to human apoB-48 bound to the anti-apoB-48 antibody immobilised on the coated plate. This reaction is stopped after 1 hour and the plate washed 4 times. Finally a peroxidase-conjugated avidin is then added to the plate. The avidin and biotin readily bind to ensure that the horseradish peroxidase enzyme is immobilised on the plate. After washing, the chromogenic substrate tetramethyl benzidine (TMB) is added. This forms a blue colour on reaction with horseradish peroxidase enzyme. The reaction stopper (1 M H~2~SO~4~) is added, resulting in a yellow colour formation which is proportional to substrate concentration. The plate was read at an absorbance of 450 nm. Interassay and intra-assay CVs were 14% and 9%, respectively.

2.6. Statistical Analysis {#sec2.6}
-------------------------

Data are presented as mean ± SEM. Skewed variables were logarithmically transformed to normalise data prior to analysis. Initial comparisons between groups were performed using independent *t*-test. Analysis of covariance (ANCOVA) was used to compare differences between the two groups adjusting for 3 separate covariates: BMI, HOMA~IR~, and *S* ~I~. Correlations were made using Pearson\'s correlation coefficient. Multiple linear regression analysis was used to identify independent contributors to postprandial TG, apoB-48, and HDL-chol. Independent variables that correlated significantly in univariate analysis were entered into the multiple regression models in forward stepwise fashion. Statistical significance was defined as *p* \< 0.05.

3. Results {#sec3}
==========

3.1. Baseline Demographic Data and Hormonal Profile {#sec3.1}
---------------------------------------------------

[Table 1](#tab1){ref-type="table"} shows the baseline data of both groups of subjects. Women with PCOS had greater BMI, WC, HC, and %BF. All androgens were higher whilst SHBG and FSH were lower in women with PCOS. Women with PCOS were more insulin resistant with a higher HOMA~IR~ (4.40 ± 0.41 *μ*mol^2^/L^2^ in PCOS versus 2.56 ± 0.30 *μ*mol^2^/L^2^ in controls) and lower *S* ~I~ (1.99 ± 0.18 × 10^−4^ min^−1^/mU/L in PCOS versus 4.05 ± 0.46 × 10^−4^ min^−1^/mU/L in controls).

3.2. Postprandial Lipids, NEFA, and Apolipoprotein {#sec3.2}
--------------------------------------------------

[Table 2](#tab2){ref-type="table"} shows the pre- and postprandial results of TG, HDL, and NEFA. Postprandial TG at 2 hours was significantly greater in PCOS women (2.18 ± 0.18 mmol/L versus 1.58 ± 0.10 mmol/L, *p* = 0.019) and nonsignificantly greater at the other time points compared to controls ([Figure 1](#fig1){ref-type="fig"}). AUC-TG, but not the iAUC-TG, was also significantly higher in women with PCOS. Conversely, HDL-chol was significantly lower in PCOS women compared to controls at *T* = 0, 2, 4, and 6 hours ([Figure 2](#fig2){ref-type="fig"}). AUC-HDL was also significantly lower in PCOS compared with controls. NEFA levels did not differ significantly between the two groups. There were no significant differences in apoA-I, apoA-II, apoB, and apoB-48 at any of the time points and the AUC or iAUC of these apolipoproteins between the two groups.

3.3. Postprandial Glucose and Insulin {#sec3.3}
-------------------------------------

[Table 3](#tab3){ref-type="table"} shows the pre- and postprandial results for glucose and insulin. Glucose levels were nonsignificantly greater at 2 hours and significantly greater at 4 hours in women with PCOS compared to controls ([Figure 3](#fig3){ref-type="fig"}). AUC-glucose was also greater in PCOS. With the exception of insulin at 8 hours, insulin level at all other time points, AUC-insulin, and iAUC-insulin were all greater in women with PCOS ([Figure 4](#fig4){ref-type="fig"}).

3.4. Comparisons following Adjustment for BMI, HOMA~IR~, and *S* ~I~ {#sec3.4}
--------------------------------------------------------------------

Tables [4](#tab4){ref-type="table"} and [5](#tab5){ref-type="table"} show results following adjustment for BMI, HOMA~IR~, and *S* ~I~. After adjusting for BMI, androgens remained higher and SHBG lower in PCOS women compared to control subjects ([Table 4](#tab4){ref-type="table"}). There were no differences in TG, HDL, and apoB-48 at any time points nor in AUC-TG, AUC-HDL, AUC-apoB-48. Insulin remained significantly higher at all time points except at 8 hours. AUC-insulin and iAUC-insulin were also significantly higher ([Table 5](#tab5){ref-type="table"}). There were no differences in the other postprandial apolipoproteins.

Following adjustment for HOMA~IR~, androgens and SHBG were significantly different between the two groups ([Table 4](#tab4){ref-type="table"}). ApoB-48 at 4 hours was significantly (*p* = 0.034) higher in the PCOS women (19.8 ± 1.68 *μ*g/mL) compared to controls (15.2 ± 1.64 *μ*g/mL) and insulin at 4 and 6 hours as well as AUC-insulin and iAUC-insulin also remained significantly higher ([Table 5](#tab5){ref-type="table"}).

Finally, following adjustment for *S* ~I~, androgens remained significantly greater in PCOS women, but SHBG was no longer significantly different ([Table 4](#tab4){ref-type="table"}). Only insulin at 4 hours was higher in the PCOS women, but AUC-insulin and iAUC-insulin were not different between the two groups ([Table 5](#tab5){ref-type="table"}). ApoB-48 was nonsignificantly (*p* = 0.058) greater at 4 hours in PCOS women (19.2 ± 1.90 *μ*g/mL) compared to controls (16.8 ± 2.00 *μ*g/mL) but not at other time points ([Table 5](#tab5){ref-type="table"}). There were no significant differences in apoB, apoA-I, or apoA-II at any of the time points or in the AUC or iAUC between the two groups.

3.5. Correlations and Multiple Regression Analyses {#sec3.5}
--------------------------------------------------

[Table 6](#tab6){ref-type="table"} shows the correlations between AUC-TG, AUC-HDL, AUC-apoB-48, AUC-apoB, AUC-glucose, AUC-insulin, and all other variables. Taking the entire cohort of 52 subjects, AUC-TG correlated positively (*p* \< 0.05 for all variables unless otherwise specified) with WC (*r* = 0.314), weight (*r* = 0.357), BMI (*r* = 0.316), and body fat content (*r* = 0.378) and negatively with body water content (*r* = −0.342) and SHBG (*r* = −0.378, *p* \< 0.01). AUC-TG did not correlate with androgens except for FAI (*r* = 0.294) and this is likely to be a result of the inverse correlation with SHBG, which causes FAI to be higher. Figures [5](#fig5){ref-type="fig"}--[8](#fig8){ref-type="fig"} show the correlations graphically between AUC-TG and SHBG ([Figure 5](#fig5){ref-type="fig"}), FAI ([Figure 6](#fig6){ref-type="fig"}), androstenedione ([Figure 7](#fig7){ref-type="fig"}), and DHEAS ([Figure 8](#fig8){ref-type="fig"}), respectively. As expected, AUC-TG also correlated strongly with HOMA~IR~, *S* ~I~ (*r* = −0.601, *p* \< 0.01), and AUC-HDL (*r* = −0.540). Insulin at 0, 2, 4, and 6 hours, AUC-insulin, and iAUC-insulin also correlated significantly with AUC-TG ([Figure 9](#fig9){ref-type="fig"}). There were also positive correlations between AUC-TG and apoB-48 at 0, 2, 6, and 8 hours, AUC-apoB-48 ([Figure 10](#fig10){ref-type="fig"}), apoB at 2, 4, 6, and 8 hours, and AUC-apoB suggesting that both chylomicrons and VLDL contribute to postprandial hypertriglyceridaemia. Glucose at 0 and 2 hours, AUC-glucose, *S* ~G~, and DI also correlated with AUC-TG. Stepwise multiple regression analysis revealed that *S* ~I~, AUC-apoB-48, and AUC-apoB were independent predictors of AUC-TG, accounting for 55% of the overall variance. This suggests that postprandial chylomicron particles probably play an important role in contributing towards postprandial hypertriglyceridaemia, together with apoB and insulin sensitivity. AUC-TG was the only independent predictor of AUC-apoB-48, explaining 25.8% of the variance.

AUC-HDL correlated significantly negatively with WC (*r* = −0.483, *p* \< 0.01), HC (*r* = −0.285), weight (*r* = −0.439, *p* \< 0.01), BMI (*r* = −0.456, *p* \< 0.01), body fat (*r* = −0.444), FAI (*r* = −0.350), HOMA~IR~ (*r* = −0.499, *p* \< 0.01), AUC-TG (*r* = −0.540, *p* \< 0.01), AUC-glucose (*r* = −0.309), and AUC-insulin (*r* = −0.488, *p* \< 0.01). AUC-HDL correlated significantly positively with body water (*r* = 0.389), SHBG (*r* = 0.443, *p* \< 0.01), and *S* ~I~ (*r* = 0.454). AUC-HDL also correlated negatively with TG at all time points, iAUC-TG, iAUC-B48, apoA-I at 2, 4, and 6 hours and AUC-apoA-I, glucose at 0 and 2 hours, AUC-glucose, insulin at 0, 2, 4, and 6 hours, AUC, and iAUC-insulin (results not shown). There was a nonsignificant negative correlation with androstenedione (*r* = −0.27, *p* = 0.055). AUC-TG and WC were the only independent predictors of AUC-HDL, explaining 37.2% of the variance using multiple regression analysis.

As expected, significant correlations were found between AUC-insulin and SHBG. AUC-insulin also correlated strongly with FAI, AUC-TG, AUC-HDL, AUC-glucose, PCOS status, and anthropometrics. Finally AUC-insulin was negatively correlated with DI, suggesting a correlation with possible subsequent *β*-cell function failure and development of diabetes.

4. Discussion {#sec4}
=============

Dyslipidaemia, including both increased TG and low HDL-cholesterol, is common in PCOS \[[@B17], [@B18]\] and is a well-recognized feature of the metabolic syndrome which confers increased risk of cardiovascular disease \[[@B19], [@B20]\]. Hypertriglyceridaemia signifies the presence of excess TRL. TRL consists of hepatically derived VLDL, characterised by the presence of apoB-100, and intestinally derived chylomicrons, which contain apoB-48. Both VLDL and chylomicrons share a common lipolytic pathway and are hydrolysed by lipoprotein lipase (LPL) and there are a number of described receptor mediated pathways through which these particles may eventually be cleared from the circulation \[[@B12]\]. It is postulated that an excess production and/or a delay in clearance of postprandial lipoproteins of both TRL particles may be implicated in atherosclerosis \[[@B21], [@B22]\].

To the best of the author\'s knowledge, this is the first study to compare the postprandial responses in obese PCOS women with that of obese control subjects. Although some postprandial studies in PCOS women have been done previously, this is the first one to evaluate the contribution of the two main metabolic/endocrine disturbances in PCOS women---IR and hyperandrogenaemia---to postprandial dyslipidaemia in obese women with PCOS. Both are implicated in accelerated atherosclerosis but the relative contribution of either is a subject of controversy \[[@B23]--[@B25]\]. Obesity, in particular central obesity, is strongly associated with insulin resistance, whilst androgens are also associated with an android distribution of fat. In a previous study by Velázquez M et al. a strong correlation between postprandial triglycerides and waist-to-hip ratio was demonstrated. That study evaluated overweight (BMI 27.41 ± 0.50 kg/m^2^) PCOS women and compared them to lean PCOS women and lean controls. Only free testosterone was measured, and there was no analysis between this and postprandial hypertriglyceridaemia \[[@B10]\]. A separate study by Bahceci et al. evaluated postprandial responses to an oral fat tolerance test, in lean PCOS women with lean controls (BMI 23.5 ± 2.6 kg/m^2^ versus 23.1 ± 4.0 kg/m^2^; *p* \> 0.05). They showed that PCOS women had higher baseline insulin, HOMA~IR~, AUC-TG, AUC-total-cholesterol, AUC-VLDL-cholesterol, and AUC-apoB. Surprisingly, though, AUC-insulin did not differ between the two groups. Again, no analyses were reported between androgens and postprandial lipids \[[@B11]\].

In this study, comparing obese women with PCOS with obese control subjects, AUC-TG, AUC-HDL, AUC-glucose, and AUC-insulin were all significantly different. HDL-chol and insulin were different at most of the time points, but TG was only different at 2 hours. Independent predictors of AUC-TG included *S* ~I~, AUC-apoB-48, and AUC-apoB, accounting for 55% of the variance. This suggests that postprandial chylomicron particles have an important role to play in postprandial hypertriglyceridaemia, together with insulin sensitivity and apoB. On the other hand, AUC-TG was the only independent predictor of AUC-apoB-48, explaining 25.8% of the variance.

Following adjustment for BMI, lipid differences were no longer noted but insulin levels at all time points and AUC-insulin and iAUC-insulin were still much greater in PCOS women consistent with the fact that PCOS women are more insulin resistant than their BMI matched counterparts \[[@B26], [@B27]\]. In this study, IR was determined by the more convenient HOMA~IR~ and insulin sensitivity was determined by the more sophisticated fsIVGTT derived *S* ~I~. When comparisons were made adjusting for HOMA~IR~, postprandial insulins were still significantly higher in the PCOS group. However, these differences were largely no longer present when adjustments were made for *S* ~I~, which may be a better marker for insulin sensitivity than HOMA~IR~, since the latter is calculated from fasting values of insulin and glucose.

There was only weak or no correlation between androgens and TG, HDL-chol, apoB-48, apoA-I, apoA-II, and apoB. There were very strong correlations between SHBG and TG, HDL-chol, AUC-apoB-48, AUC-apoB, and AUC-apoA-II. FAI but not testosterone*per se* also strongly correlated with HDL at all time points, TG at 0 and 2 hours, and both AUC-HDL-chol and AUC-TG. This suggests that IR, and perhaps obesity, both of which are strongly negatively correlated with SHBG, rather than androgens, may be the major determinant of postprandial lipids.

This study had certain limitations. PCOS women and the controls were not entirely matched for BMI. However, both groups were obese and results were analyzed with BMI as a covariate. The two groups did not match for IR as assessed by HOMA~IR~ nor *S* ~I~ as assessed by the fsIVGTT. However this is to be expected based on the well accepted notion that women with PCOS are more insulin resistant than BMI matched counterparts. In addition, after using HOMA~IR~ and *S* ~I~ as covariates, results still revealed that hyperinsulinaemia and possibly a low SHBG level are the main factors influencing postprandial hypertriglyceridaemia. Postprandial chylomicrons also appear to play a significant role in postprandial hypertriglyceridaemia in premenopausal women with and without PCOS.

In conclusion, this study provides evidence that, in obese women with PCOS, IR plays a more important role than hyperandrogenaemia in postprandial dyslipidaemia and cardiovascular risk. Targeting obesity and thereby improving IR by lifestyle measures and perhaps the use of agents such as metformin should be a priority in the treatment of obese PCOS women.
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###### 

Baseline characteristics of all subjects (*n* = 52).

  -------------------------------------------------------------------------------
                                        PCOS\           Controls\       *p*
                                        (*n* = 26)      (*n* = 26)      
  ------------------------------------- --------------- --------------- ---------
  Age (yrs)                             30.4 ± 1.2      34.1 ± 1.5      0.063

  Systolic BP (mmHg)                    126.3 ± 1.8     121.6 ± 2.5     0.131

  Diastolic BP (mmHg)                   79.0 ± 1.1      77.8 ± 2.3      0.652

  Waist (cm)                            112.0 ± 2.2     99.8 ± 2.4      \<0.001

  Hip (cm)                              120.5 ± 1.7     110.9 ± 1.9     \<0.001

  Waist : Hip                           0.930 ± 0.014   0.900 ± 0.014   0.139

  Weight (kg)                           95.4 ± 2.6      83.2 ± 2.8      0.003

  BMI (kg/m^2^)                         36.8 ± 0.9      31.5 ± 1.0      \<0.001

  Smoking (%)                           26              31              0.696

  \% Body fat mass (%)                  40.4 ± 1.3      33.6 ± 2.0      0.006

  T (nmol/L)^*∗*^                       3.22 ± 0.30     1.57 ± 0.13     \<0.001

  SHBG (nmol/L)^*∗*^                    29.8 ± 2.00     47.4 ± 3.48     \<0.001

  FAI^*∗*^                              12.2 ± 1.59     3.67 ± 0.39     \<0.001

  Androstenedione (nmol/L)              15.58 ± 0.84    11.82 ± 0.84    0.003

  DHEAS (*μ*mol/L)                      7.62 ± 0.71     4.98 ± 0.49     0.003

  FSH (IU/L)^*∗*^                       5.54 ± 0.35     8.93 ± 0.90     \<0.001

  LH (IU/L)^*∗*^                        6.37 ± 0.74     7.49 ± 1.41     0.654

  HOMA~IR~ (*μ*mol^2^/L^2^)^*∗*^        4.40 ± 0.41     2.56 ± 0.30     \<0.001

  *S* ~I~ (×10^−4^ min^−1^/mU/L)^*∗*^   1.99 ± 0.18     4.05 ± 0.46     \<0.001

  *S* ~G~ (min^−1^)                     0.02 ± 0.00     0.02 ± 0.00     0.352

  AIR~G~ (mU·L^−1^·min)^*∗*^            985 ± 171       613 ± 85        0.207

  DI                                    1756 ± 281      2308 ± 358      0.226
  -------------------------------------------------------------------------------

^*∗*^ *t*-tests analysis after log transformation.

###### 

Postprandial triglycerides, HDL-chol, NEFA, and apolipoproteins.

                                     PCOS (*n* = 26)   Controls (*n* = 26)   *p*
  ---------------------------------- ----------------- --------------------- -------
  TG 0 hrs (mmol/L)^*∗*^             1.57 ± 0.15       1.20 ± 0.08           0.075
  TG 2 hrs (mmol/L)^*∗*^             2.18 ± 0.18       1.58 ± 0.10           0.019
  TG 4 hrs (mmol/L)^*∗*^             2.41 ± 0.22       1.83 ± 0.14           0.057
  TG 6 hrs (mmol/L)^*∗*^             1.96 ± 0.23       1.49 ± 0.16           0.074
  TG 8 hrs (mmol/L)^*∗*^             1.74 ± 0.22       1.30 ± 0.13           0.129
  AUC-TG (mmol/L·8 hrs)^*∗*^         8.20 ± 0.77       6.15 ± 0.45           0.041
  iAUC-TG (mmol/L·8 hrs)             1.93 ± 0.28       1.35 ± 0.24           0.127
  HDL-chol 0 hrs (mmol/L)            1.34 ± 0.06       1.51 ± 0.06           0.046
  HDL-chol 2 hrs (mmol/L)            1.27 ± 0.06       1.44 ± 0.05           0.037
  HDL-chol 4 hrs (mmol/L)            1.22 ± 0.06       1.37 ± 0.05           0.043
  HDL-chol 6 hrs (mmol/L)            1.25 ± 0.06       1.42 ± 0.05           0.034
  HDL-chol 8 hrs (mmol/L)            1.30 ± 0.06       1.44 ± 0.05           0.092
  AUC-HDL-chol (mmol/L·8 hrs)        5.06 ± 0.23       5.71 ± 0.21           0.041
  iAUC-HDL-chol (mmol/L·8 hrs)       −0.32 ± 0.03      −0.33 ± 0.07          0.883
  NEFA 0 hrs (mmol/L)                0.65 ± 0.04       0.61 ± 0.05           0.644
  NEFA 2 hrs (mmol/L)                0.19 ± 0.02       0.18 ± 0.05           0.658
  NEFA 4 hrs (mmol/L)                0.33 ± 0.03       0.36 ± 0.05           0.524
  NEFA 6 hrs (mmol/L)                0.62 ± 0.05       0.67 ± 0.05           0.544
  NEFA 8 hrs (mmol/L)                0.81 ± 0.05       0.84 ± 0.05           0.698
  AUC NEFA (mmol/L·8 hrs)            1.87 ± 0.10       1.94 ± 0.05           0.681
  iAUC NEFA (mmol/L·8 hrs)           −0.72 ± 0.14      −0.52 ± 0.05          0.400
  ApoB-48 0 hrs (*μ*g/mL)^*∗*^       11.9 ± 1.45       9.89 ± 1.29           0.252
  ApoB-48 2 hrs (*μ*g/mL)^*∗*^       17.0 ± 1.43       15.7 ± 1.08           0.468
  ApoB-48 4 hrs (*μ*g/mL)^*∗*^       19.2 ± 1.56       15.8 ± 1.55           0.058
  ApoB-48 6 hrs (*μ*g/mL)^*∗*^       18.3 ± 1.70       15.8 ± 1.93           0.184
  ApoB-48 8 hrs (*μ*g/mL)^*∗*^       12.9 ± 1.34       11.3 ± 1.48           0.239
  AUC-apoB-48 (*μ*g/mL·8 hrs)^*∗*^   66.4 ± 5.32       57.6 ± 4.41           0.157
  iAUC-apoB-48 (*μ*g/mL·8 hrs)       19.35 ± 3.38      18.27 ± 2.45          0.796
  ApoB 0 hrs (g/dL)                  0.73 ± 0.07       0.82 ± 0.06           0.328
  ApoB 2 hrs (g/dL)                  0.76 ± 0.07       0.73 ± 0.06           0.816
  ApoB 4 hrs (g/dL)                  0.83 ± 0.06       0.76 ± 0.06           0.364
  ApoB 6 hrs (g/dL)                  0.79 ± 0.05       0.77 ± 0.05           0.779
  ApoB 8 hrs (g/dL)                  0.83 ± 0.05       0.79 ± 0.05           0.603
  AUC-apoB (g/dL·8 hrs)              3.16 ± 0.17       3.07 ± 0.14           0.688
  iAUC-apoB (g/dL·8 hrs)             0.22 ± 0.22       −0.22 ± 0.19          0.143
  ApoA-I 0 hrs (g/dL)                1.15 ± 0.07       1.10 ± 0.10           0.679
  ApoA-I 2 hrs (g/dL)                1.04 ± 0.09       1.14 ± 0.09           0.437
  ApoA-I 4 hrs (g/dL)                1.19 ± 0.08       1.28 ± 0.08           0.465
  ApoA-I 6 hrs (g/dL)                1.18 ± 0.08       1.22 ± 0.08           0.715
  ApoA-I 8 hrs (g/dL)                1.08 ± 0.08       1.16 ± 0.09           0.481
  AUC-apoA-I (g/dL·8 hrs)            4.52 ± 0.19       4.75 ± 0.18           0.391
  iAUC-apoA-I (g/dL·8 hrs)           −0.08 ± 0.30      0.35 ± 0.34           0.342
  ApoA-II 0 hrs (g/dL)               0.32 ± 0.02       0.30 ± 0.03           0.544
  ApoA-II 2 hrs (g/dL)               0.29 ± 0.03       0.30 ± 0.02           0.796
  ApoA-II 4 hrs (g/dL)               0.26 ± 0.03       0.25 ± 0.03           0.764
  ApoA-II 6 hrs (g/dL)               0.26 ± 0.02       0.30 ± 0.02           0.195
  ApoA-II 8 hrs (g/dL)               0.25 ± 0.02       0.26 ± 0.02           0.761
  AUC-apoA-II (g/dL·8 hrs)           1.10 ± 0.04       1.13 ± 0.04           0.657
  iAUC-apoA-II (g/dL·8 hrs)          −0.19 ± 0.09      −0.08 ± 0.09          0.410

^*∗*^ *t*-tests analysis after log transformation.

###### 

Postprandial glucose and insulin.

  ------------------------------------------------------------------------
                                   PCOS\          Controls\      *p*
                                   (*n* = 26)     (*n* = 26)     
  -------------------------------- -------------- -------------- ---------
  Glucose 0 hrs (mmol/L)           5.18 ± 0.11    4.99 ± 0.10    0.191

  Glucose 2 hrs (mmol/L)           5.67 ± 0.30    4.90 ± 0.25    0.053

  Glucose 4 hrs (mmol/L)           5.18 ± 0.18    4.73 ± 0.12    0.044

  Glucose 6 hrs (mmol/L)           4.66 ± 0.08    4.66 ± 0.06    0.959

  Glucose 8 hrs (mmol/L)           4.66 ± 0.06    4.62 ± 0.09    0.713

  AUC-glucose (mmol/L·8 hrs)       20.50 ± 0.48   19.10 ± 0.38   0.024

  iAUC-glucose (mmol/L·8 hrs)      −0.33 ± 0.32   −0.86 ± 0.40   0.306

  Insulin 0 hrs (mU/L)^*∗*^        19.3 ± 1.80    11.7 ± 1.28    \<0.001

  Insulin 2 hrs (mU/L)^*∗*^        105 ± 13.8     47.6 ± 5.41    \<0.001

  Insulin 4 hrs (mU/L)^*∗*^        49.9 ± 7.02    21.4 ± 2.21    \<0.001

  Insulin 6 hrs (mU/L)^*∗*^        21.7 ± 2.35    10.4 ± 0.85    \<0.001

  Insulin 8 hrs (mU/L)^*∗*^        15.3 ± 1.59    12.6 ± 2.05    0.084

  AUC-insulin (mU/L·8 hrs)^*∗*^    194 ± 21.6     91.5 ± 8.03    \<0.001

  iAUC-insulin (mU/L·8 hrs)^*∗*^   117 ± 17.5     44.8 ± 5.70    \<0.001
  ------------------------------------------------------------------------

^*∗*^ *t*-tests analysis after log transformation.

###### 

Baseline characteristics adjusted for BMI, HOMA~IR~, and log *S* ~I~.

                                        Covariate: BMI   Covariate: HOMA~IR~   Covariate: *S* ~I~                                     
  ------------------------------------- ---------------- --------------------- -------------------- --------------- ----------------- ---------------
  Systolic BP (mmHg)                    124.6 ± 2.2      123.3 ± 2.2           124.4 ± 2.2          123.5 ± 2.2     125.0 ± 2.4       123.0 ± 2.6
  Diastolic BP (mmHg)                   78.0 ± 1.9       78.9 ± 1.9            78.6 ± 2.0           78.2 ± 2.0      78.6 ± 2.1        78.9 ± 2.3
  Waist (cm)                            107.3 ± 1.5      104.5 ± 1.5           109.0 ± 2.2          102.8 ± 2.2     108.8 ± 2.4       104.3 ± 2.6
  Hip (cm)                              116.6 ± 1.1      114.8 ± 1.1           118.7 ± 1.9^a^       112.6 ± 1.9     118.4 ± 2.0       113.3 ± 2.2
  Waist : Hip                           0.920 ± 0.015    0.910 ± 0.015         0.917 ± 0.015        0.913 ± 0.015   0.919 ± 0.016     0.921 ± 0.017
  Weight (kg)                           89.2 ± 1.4       89.5 ± 1.4            91.2 ± 2.5           87.4 ± 2.5      91.0 ± 2.8        88.9 ± 3.0
  BMI (kg/m^2^)                         ---              35.3 ± 1.0            32.9 ± 0.9           35.4 ± 1.1      33.7 ± 1.2        
  \% Body fat mass (%)                  37.6 ± 1.2       36.2 ± 1.2            38.2 ± 1.7           35.7 ± 1.7      38.5 ± 1.8        36.2 ± 1.9
  T (nmol/L)^*∗*^                       3.37 ± 0.25^b^   1.52 ± 0.24           3.24 ± 0.25^b^       1.56 ± 0.25     3.49 ± 0.27^b^    1.30 ± 0.279
  SHBG (nmol/L)^*∗*^                    32.2 ± 3.04^b^   45.2 ± 2.98           31.4 ± 2.98^b^       45.7 ± 2.98     34.2 ± 3.19       43.4 ± 3.45
  FAI^*∗*^                              12.2 ± 1.25^b^   4.08 ± 1.22           12.2 ± 1.24^b^       3.70 ± 1.24     12.5 ± 1.38^b^    3.30 ± 1.50
  Androstenedione (nmol/L)              15.67 ± 0.9^b^   11.99 ± 0.89          15.07 ± 0.92^a^      12.30 ± 0.90    15.98 ± 0.99^b^   11.37 ± 1.05
  DHEAS (*μ*mol/L)                      8.00 ± 0.68^b^   4.80 ± 0.66           7.88 ± 0.66          4.72 ± 0.66     8.55 ± 0.66^b^    3.80 ± 0.72
  HOMA~IR~ (*μ*mol^2^/L^2^)^*∗*^        3.99 ± 0.35^a^   3.02 ± 0.34           ---                  3.91 ± 0.38     3.39 ± 0.41       
  *S* ~I~ (×10^−4^ min^−1^/mU/L)^*∗*^   2.23 ± 0.31^b^   3.78 ± 0.34           2.33 ± 0.30^a^       3.66 ± 0.32     ---               
  *S* ~G~ (min^−1^)                     0.02 ± 0.00      0.02 ± 0.00           0.02 ± 0.00          0.02 ± 0.00     0.02 ± 0.00       0.02 ± 0.00
  AIR~G~ (mU·L^−1^·min)^*∗*^            986 ± 144        612 ± 155             867 ± 133            747 ± 143       909 ± 149         700 ± 161
  DI                                    1846 ± 321       2206 ± 345            1893 ± 326           2151 ± 351      2174 ± 312        1831 ± 338

^*∗*^ANCOVA analysis after log transformation. ^a^ *p* \< 0.05 versus controls. ^b^ *p* \< 0.01 versus controls.

###### 

Postprandial TG, HDL, apoB-48, glucose, and insulin levels adjusted for BMI, HOMA~IR~, and *S* ~I~.

                                     Covariate: BMI   Covariate: HOMA~IR~   Covariate: *S* ~I~                                   
  ---------------------------------- ---------------- --------------------- -------------------- -------------- ---------------- --------------
  TG 0 hrs (mmol/L)^*∗*^             1.54 ± 0.13      1.25 ± 0.12           1.40 ± 0.11          1.36 ± 0.11    1.47 ± 0.13      1.33 ± 0.14
  TG 2 hrs (mmol/L)^*∗*^             2.14 ± 0.16      1.66 ± 0.16           1.97 ± 0.14          1.79 ± 0.14    2.04 ± 0.17      1.73 ± 0.18
  TG 4 hrs (mmol/L)^*∗*^             2.37 ± 0.20      1.90 ± 0.19           2.14 ± 0.16          2.10 ± 0.16    2.24 ± 0.20      2.10 ± 0.22
  TG 6 hrs (mmol/L)^*∗*^             1.92 ± 0.21      1.57 ± 0.21           1.70 ± 0.18          1.75 ± 0.18    1.80 ± 0.22      1.77 ± 0.24
  TG 8 hrs (mmol/L)^*∗*^             1.71 ± 0.19      1.37 ± 0.19           1.48 ± 0.16          1.56 ± 0.16    1.60 ± 0.20      1.56 ± 0.22
  AUC-TG (mmol/L·8 hrs)^*∗*^         8.06 ± 0.68      6.45 ± 0.66           7.25 ± 0.54          7.10 ± 0.54    7.61 ± 0.70      7.04 ± 0.76
  iAUC-TG (mmol/L·8 hrs)             1.87 ± 0.29      1.45 ± 0.29           1.63 ± 0.27          1.65 ± 0.27    1.64 ± 0.31      1.82 ± 0.33
  HDL-chol 0 hrs (mmol/L)            1.40 ± 0.06      1.45 ± 0.06           1.41 ± 0.06          1.44 ± 0.06    1.40 ± 0.06      1.38 ± 0.07
  HDL-chol 2 hrs (mmol/L)            1.33 ± 0.06      1.38 ± 0.06           1.34 ± 0.05          1.37 ± 0.05    1.34 ± 0.06      1.33 ± 0.07
  HDL-chol 4 hrs (mmol/L)            1.27 ± 0.06      1.32 ± 0.05           1.28 ± 0.05          1.31 ± 0.05    1.28 ± 0.06      1.27 ± 0.06
  HDL-chol 6 hrs (mmol/L)            1.30 ± 0.06      1.37 ± 0.06           1.32 ± 0.06          1.36 ± 0.06    1.31 ± 0.06      1.31 ± 0.07
  HDL-chol 8 hrs (mmol/L)            1.35 ± 0.06      1.38 ± 0.06           1.36 ± 0.06          1.37 ± 0.06    1.36 ± 0.06      1.32 ± 0.07
  AUC-HDL-chol (mmol/L·8 hrs)        5.28 ± 0.23      5.49 ± 0.22           5.33 ± 0.22          5.44 ± 0.22    5.31 ± 0.24      5.26 ± 0.26
  iAUC-HDL-chol (mmol/L·8 hrs)       −0.33 ± 0.06     −0.31 ± 0.06          −0.33 ± 0.06         −0.32 ± 0.06   −0.30 ± 0.06     −0.27 ± 0.07
  ApoB-48 0 hrs (*μ*g/mL)^*∗*^       12.4 ± 1.54      9.70 ± 1.47           11.9 ± 1.49          9.86 ± 1.46    11.9 ± 1.70      10.4 ± 1.80
  ApoB-48 2 hrs (*μ*g/mL)^*∗*^       17.3 ± 1.43      15.6 ± 1.36           17.0 ± 1.37          15.7 ± 1.34    16.5 ± 1.53      16.9 ± 1.62
  ApoB-48 4 hrs (*μ*g/mL)^*∗*^       19.6 ± 1.77      15.5 ± 1.69           19.8 ± 1.68^a^       15.2 ± 1.64    19.2 ± 1.90      16.8 ± 2.00
  ApoB-48 6 hrs (*μ*g/mL)^*∗*^       18.9 ± 2.06      15.6 ± 1.97           17.2 ± 1.94          16.9 ± 1.90    17.9 ± 2.22      17.5 ± 2.34
  ApoB-48 8 hrs (*μ*g/mL)^*∗*^       13.2 ± 1.60      11.2 ± 1.53           11.7 ± 1.47          12.4 ± 1.44    12.3 ± 1.70      12.5 ± 1.79
  Log ApoB-48 (*μ*g/mL·8 hrs)^*∗*^   67.8 ± 5.51      57.1 ± 5.26           65.6 ± 5.30          58.4 ± 5.18    65.0 ± 5.97      62.5 ± 6.30
  iAUC apoB-48 (*μ*g/mL·8 hrs)       19.02 ± 3.33     18.31 ± 3.18          17.57 ± 3.19         19.98 ± 3.12   17.92 ± 3.70     21.06 ± 3.91
  Insulin 0 hrs (pmol/L)^*∗*^        17.9 ± 1.56^a^   13.4 ± 1.2            15.4 ± 0.30          15.6 ± 0.30    17.5 ± 1.66      15.1 ± 1.79
  Insulin 2 hrs (pmol/L)^*∗*^        95.7 ± 10.3^a^   59.5 ± 10.1           88.7 ± 8.91          63.8 ± 8.91    91.6 ± 11.3      64.1 ± 12.2
  Insulin 4 hrs (pmol/L)^*∗*^        47.6 ± 5.59^b^   24.6 ± 5.47           43.7 ± 4.92^a^       27.6 ± 4.92    45.7 ± 5.94^b^   27.7 ± 6.42
  Insulin 6 hrs (pmol/L)^*∗*^        20.9 ± 1.90^b^   11.6 ± 1.86           19.2 ± 1.57^b^       12.9 ± 1.57    19.9 ± 1.94      13.2 ± 2.11
  Insulin 8 hrs (pmol/L)^*∗*^        13.6 ± 1.89      14.4 ± 1.84           13.4 ± 1.81          14.3 ± 1.81    14.1 ± 2.17      14.7 ± 2.35
  AUC-insulin (pmol/L·8 hrs)^*∗*^    180 ± 16.2^b^    110 ± 15.8            166 ± 13.0^a^        119 ± 13.0     173 ± 17.5       120 ± 18.9
  iAUC-insulin (pmol/L·8 hrs)^*∗*^   108 ± 13.5^a^    55.9 ± 13.2           104 ± 13.0^a^        57.0 ± 13.0    103 ± 14.7       59.6 ± 15.9

^*∗*^ANCOVA analysis after log transformation. ^a^ *p* \< 0.05 versus controls. ^b^ *p* \< 0.01 versus controls.

###### 

Correlations between AUC-TG, AUC-HDL-chol, AUC-apoB-48, AUC-apoB, AUC-glucose, AUC-insulin, and other variables.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                     AUC-TG^*∗*^ \    AUC-HDL \        AUC-apoB-48^*∗*^ \   AUC-B \        AUC-glucose \    AUC-insulin^*∗*^ \
                                                                     (mmol/L·8 hrs)   (mmol/L·8 hrs)   (*μ*g/mL·8 hrs)      (g/dL·8 hrs)   (mmol/L·8 hrs)   (pmol/L·8 hrs)
  ------------------------------------------------------------------ ---------------- ---------------- -------------------- -------------- ---------------- --------------------
  AUC-TG^*∗*^ (mmol/L·8 hrs)                                         1.000            −0.540^b^        0.524^b^             0.484^b^       0.304^a^         0.542^b^

  AUC-HDL-chol (mmol/L·8 hrs)                                        −0.540^b^        1.000            −0.229               −0.225         −0.309^a^        −0.488^b^

  AUC-apoB-48^*∗*^ (*μ*g/mL·8 hrs)                                   0.524^b^         −0.229           1.000                0.298^a^       0.171            0.165

  AUC-apoB (g/dL·8 hrs)                                              0.484^b^         −0.225           0.298^a^             1.000          0.038            0.206

  AUC-glucose (mmol/L·8 hrs)                                         0.304^a^         −0.309^a^        0.171                0.038          1.000            0.634^b^

  AUC-insulin^*∗*^ (pmol/L·8 hrs)                                    0.542^b^         −0.488^b^        0.165                0.206          0.634^b^         1.000

                                                                                                                                                            

   Age, PCOS status                                                                                                                                         

  Age (years)                                                        0.125            −0.010           −0.025               0.134          0.342^a^         −0.014

  PCOS                                                               0.284^a^         −0.284^a^        0.201                0.057          0.315^a^         0.579^b^

                                                                                                                                                            

   Androgens, SHBG                                                                                                                                          

  T^*∗*^ (nmol/L)                                                    0.133            −0.163           0.115                −0.023         0.092            0.331

  SHBG^*∗*^ (nmol/L)                                                 −0.378^b^        0.443^b^         −0.277^a^            −0.277^a^      −0.305^a^        −0.550^b^

  FAI^*∗*^                                                           0.294^a^         −0.350^a^        0.227                0.125          0.226            0.530^b^

  Androstenedione (nmol/L)                                           0.078            −0.271           −0.014               −0.056         0.146            0.416

  DHEAS (*μ*mol/L)                                                   −0.068           −0.048           0.108                −0.289^a^      0.125            0.158

                                                                                                                                                            

   Anthropometrics                                                                                                                                          

  Waist (cm)                                                         0.314^a^         −0.483^b^        0.063                0.080          0.372^b^         0.661^b^

  Hip (cm)                                                           0.216            −0.285^a^        −0.064               0.154          0.356^a^         0.609^b^

  Waist : Hip                                                        0.237            −0.439^b^        0.163                −0.047         0.193            0.360^a^

  Weight (kg)                                                        0.357^a^         −0.378^b^        0.059                0.276          0.271            0.639^b^

  BMI (kg/m^2^)                                                      0.316^a^         −0.456^b^        0.033                0.184          0.414^b^         0.686^b^

  \% Body fat mass (%)                                               0.378^a^         −0.444^b^        0.009                0.164          0.368^a^         0.539^b^

  \% Body lean mass (%)                                              −0.128           0.240            0.085                −0.152         −0.348^a^        −0.381^a^

  \% Body water (%)                                                  −0.342^a^        0.389^a^         −0.031               −0.178         −0.314           −0.487^b^

                                                                                                                                                            

   IR, insulin sensitivity, and variables derived from the fsIVGTT                                                                                          

  HOMA~IR~ ^*∗*^ (*μ*mol^2^/L^2^)                                    0.568^b^         −0.499^b^        0.130                0.229          0.366^b^         0.800^b^

  *S* ~I~ (×10^−4^ min^−1^/mU/L)^*∗*^                                −0.601^b^        0.454^b^         −0.223               −0.262         −0.453^b^        −0.810^b^

  *S* ~G~ (min^−1^)                                                  −0.364^a^        0.159            −0.266               −0.232         −0.083           −0.171

  AIR~G~ (mU·L^−1^·min)^*∗*^                                         0.029            −0.090           −0.282               0.100          −0.410^b^        0.153

  DI                                                                 −0.364^a^        0.226            −0.328^a^            −0.139         −0.558^b^        −0.391^b^
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^*∗*^Correlations after log transformation.

^a^ *p* \< 0.05. ^b^ *p* \< 0.01.

[^1]: Academic Editor: TongJin Zhao
